Slides from my recent talk at @AMRCongress on tele-stewardship implementation, models, and how it can aid in bridging the gap in access to ID/ASP services
1/n
Dosing of antimicrobials in patients with new AKI
- this has been a long term area of interest from this renal pharmacist who has retrained in infection
Here we present our latest real-world data https://t.co/MMz3zpD4OD 1/nbe
Given resistance to azithromycin and toxicity of fluoroquinolones, doxycycline for CAP has tremendous appeal. This systematic review of clinical trials suggests has comparable efficacy. @CIDJournal https://t.co/4bUWF7Z99W
After years of improvement, new CDC data show #COVID19 pandemic has reversed the nation’s progress on #AntimicrobialResistance. Report shows resistant hospital-onset infections & deaths both increasing ≥15% in 2020. Read full report: https://t.co/vpAkEiyMk0.
Just published💥 @AJHPOfficial
The first systematic review to summarize the available published data on the stability of antibiotics in portable elastomeric infusion devices #IDTwitter#opat#TwitteRx#MedEd
https://t.co/uozI0cx3bN
Now that you've matched to your dream pharmacy residency program, what's next? Have questions about licensing, moving to a new city or picking a research project? Join our @SIDPharm and @ASHPOfficial Twitter Chat on Wednesday @ 7pm ET to get your questions answered! #RxResiChat
A review of 229 adult inpatients with invasive pneumococcal disease in OFID found that just 14% were vaccinated, with numerous missed vaccination opportunities across different care settings.
📄:https://t.co/d2ByHF6ld1
@PaulSaxMD@DrJLi@AshabeeWilde@lessabxismoore
IDSA releases updated AMR Gram Negative Guidance on the treatment of infections caused by ESBL-E, CRE, and DTR-P. aeruginosa: https://t.co/xesmEZkhEv
#IDSAGuidelines#antimicrobialresistance
@VidhyaPrakashIL Your stories were fantastic! My Air Force Veteran hubs got a kick out of your training stories too ☺️. Thank you for sharing your words and lessons!